drugset / Trial / NCT04855136
Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a global, open-label, multi-arm, multi-cohort, multi-center, phase 1/2 study to determine the safety, tolerability, efficacy, PK of bb2121 in combination with other therapies in adult subjects with R/RMM. The following combinations will be * Arm A will test bb2121 in combination with CC-220 (± low-dose dexamethasone) * Arm B will test bb2121 in combination with BMS-986405 (JSMD194) Combination agents being tested may be administered before, concurrently with and/or following (ie, maintenance) bb2121 infusion. The study will consist of 2 parts: dose finding (Phase 1) and dose expansion (Phase 2). Dose expansion may occur in one or more arms.
Timeline
- Start
- 2021-06-01
- Primary completion
- 2025-04-25
- Completion
- 2025-04-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BMS-986405 | Unknown | — | — |
| Subject | Iberdomide | Small molecule | — | — |
| Subject | idecabtagene vicleucel | Cell therapy | 4.5e+08 cells | — |